Erythrocyte membrane camouflaged graphene oxide for tumor-targeted photothermal-chemotherapy

Nanodrug carrier-based cancer therapy has been actively developed in the past decades. The main challenges faced by nanodrug carriers include poor drug loading capacity, rapid clearance from blood circulation, and low antitumor efficiency. In this work, a new type of antineoplastic agents, F-RGID, w...

Full description

Saved in:
Bibliographic Details
Published in:Carbon (New York) 2019-05, Vol.146, p.660-670
Main Authors: Li, Jian, Huang, Xueyuan, Huang, Rong, Jiang, Jing, Wang, Yanjie, Zhang, Junhua, Jiang, Haiye, Xiang, Xinying, Chen, Wansong, Nie, Xinmin, Gui, Rong
Format: Article
Language:English
Subjects:
Biocompatibility
Bionics
Blood circulation
Cancer therapies
Chemotherapy
Doxorubicin
Drug delivery systems
Erythrocytes
Folic acid
Graphene
Lipids
Nanoparticles
Photosynthesis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nanodrug carrier-based cancer therapy has been actively developed in the past decades. The main challenges faced by nanodrug carriers include poor drug loading capacity, rapid clearance from blood circulation, and low antitumor efficiency. In this work, a new type of antineoplastic agents, F-RGID, were developed using a two-dimensional graphene oxide (GO) with an incorporated photosensitizer (Indocyanine Green, ICG) and a chemotherapeutic drug (Doxorubicin, DOX) as the internally wrapped nanoparticles, and the RBC membrane (RM) inserted with the targeting molecule (folic acid, F) as a shell. The endogenous nature of RM confers F-RGID excellent biocompatibility and the ability to evade from clearance by the reticuloendothelial system (RES). In addition, F-RGID is decorated with folic acid for selective recognition of tumor cells via a lipid-insertion approach. Another salient feature of the antineoplastic platform is the combination of photothermal-chemotherapy with ICG and DOX. In vitro and in vivo experiments revealed that F-RGID could provide a bionic nanoplatform for tumor-targeted photothermal-chemotherapy in clinic. A new type of antineoplastic agents, F-RGID, were developed using a two-dimensional graphene oxide (GO) with an incorporated photosensitizer (Indocyanine Green, ICG) and a chemotherapeutic drug (Doxorubicin, DOX) as the internally wrapped nanoparticles, and the RBC membrane (RM) inserted with the targeting molecule (folic acid, F) as a shell. [Display omitted]
ISSN:0008-6223
1873-3891
DOI:10.1016/j.carbon.2019.02.056